GeoVax's Cash Dwindles Amidst Rising Losses, Government Revenue Plummets

TL;DR

**GOVX is burning cash faster than it can raise it, making it a high-risk bet with a 'going concern' warning that screams 'avoid'.**

AI Summary

GeoVax Labs, Inc. reported a net loss of $6,318,914 for the three months ended September 30, 2025, an increase from a net loss of $5,815,468 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $17,046,348, compared to $16,729,642 in the prior year. Revenue from government contracts significantly decreased to $0 for the three months ended September 30, 2025, from $2,789,484 in 2024, and for the nine-month period, it fell to $2,489,145 from $3,090,161. Research and development expenses decreased to $5,043,504 for the three-month period in 2025 from $7,402,884 in 2024, while general and administrative expenses increased to $1,329,711 from $1,241,176. The company raised approximately $2.3 million from a September 2025 offering, $5.5 million from a July 2025 offering, and $4.1 million from a March 2025 offering, alongside $4.0 million from its ATM program during the nine months ended September 30, 2025. GeoVax's cash and cash equivalents decreased to $5,008,997 as of September 30, 2025, from $5,506,941 at December 31, 2024, and the company explicitly stated that its existing cash resources will only be sufficient into late fourth quarter of 2025, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

GeoVax's substantial net losses and declining government contract revenue signal significant operational challenges, directly impacting investor confidence and the company's ability to fund its critical clinical trials for vaccines like GEO-CM04S1 and Gedeptin. The explicit 'going concern' warning indicates a high risk of further dilution for existing shareholders or potential insolvency if additional capital isn't secured quickly. For employees, this raises job security concerns, and for patients awaiting their therapies, it introduces uncertainty about future development. In the competitive biotech landscape, GeoVax's struggle to maintain funding could see it fall behind rivals in vaccine and immunotherapy development.

Risk Assessment

Risk Level: high — GeoVax explicitly states that its existing cash resources of $5,008,997 as of September 30, 2025, will only be sufficient to continue planned operations into late fourth quarter of 2025, raising 'substantial doubt about the Company's ability to continue as a going concern.' This, coupled with a net loss of $17,046,348 for the nine months ended September 30, 2025, and a significant drop in government contract revenue to $0 for the three months ended September 30, 2025, indicates severe financial instability.

Analyst Insight

Investors should exercise extreme caution and consider divesting from GOVX given the explicit 'going concern' warning and rapid cash burn. Prospective investors should avoid initiating a position until the company demonstrates a clear path to sustainable funding and profitability, as significant dilution or even bankruptcy remains a distinct possibility.

Financial Highlights

debt To Equity

0.37

revenue

$2,489,145

operating Margin

-702.8%

total Assets

$6,731,255

total Debt

$1,824,177

net Income

-$17,046,348

eps

-$0.97

gross Margin

N/A

cash Position

$5,008,997

revenue Growth

-19.4%

Revenue Breakdown

Key Numbers

• $6,318,914 — Net Loss (Q3 2025) (Increased from $5,815,468 in Q3 2024)
• $17,046,348 — Net Loss (YTD Sep 2025) (Increased from $16,729,642 in YTD Sep 2024)
• $0 — Government Contract Revenue (Q3 2025) (Significant decrease from $2,789,484 in Q3 2024)
• $2,489,145 — Government Contract Revenue (YTD Sep 2025) (Decreased from $3,090,161 in YTD Sep 2024)
• $5,008,997 — Cash and Cash Equivalents (Sep 30, 2025) (Decreased from $5,506,941 at Dec 31, 2024)
• $15,885,652 — Net Proceeds from Stock and Warrants (YTD Sep 2025) (Primary source of funding, but insufficient to cover losses)
• 29,705,360 — Shares Outstanding (Nov 13, 2025) (Increased significantly from 10,536,875 at Dec 31, 2024, indicating dilution)
• $0.31 — Net Loss Per Share (Q3 2025) (Lower than $0.91 in Q3 2024 due to increased share count)
• $0.97 — Net Loss Per Share (YTD Sep 2025) (Lower than $4.52 in YTD Sep 2024 due to increased share count)
• $1,619,481 — Unrecognized Stock-Based Compensation Expense (To be recognized over a weighted-average period of 2.1 years)

Key Players & Entities

• GeoVax Labs, Inc. (company) — registrant of the 10-Q filing
• GEO-CM04S1 (product) — lead clinical program, multi-antigen, next-generation COVID-19 vaccine
• Gedeptin (product) — lead clinical program, novel oncolytic solid tumor gene-directed therapy
• Nasdaq Capital Market (market) — exchange where GOVX common stock is registered
• Biomedical Advanced Research and Development Authority (regulator) — funding source for the Rapid Response Partnership Vehicle (RRPV)
• September 30, 2025 (date) — end of the reporting period for the 10-Q
• December 31, 2024 (date) — prior fiscal year-end for balance sheet comparison
• November 13, 2025 (date) — filing date of the 10-Q
• Smyrna, Georgia (location) — address of principal executive offices
• Delaware (location) — state of incorporation

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company explicitly stated that its existing cash resources will only be sufficient into late fourth quarter of 2025. This raises substantial doubt about its ability to continue as a going concern, given the increasing net losses and declining cash position.
• Increasing Net Losses [high — financial]: Net loss for Q3 2025 was $6,318,914, an increase from $5,815,468 in Q3 2024. Year-to-date net loss through September 30, 2025, was $17,046,348, up from $16,729,642 in the prior year, indicating deteriorating profitability.
• Dependence on Equity Offerings [high — financial]: The company raised approximately $15.89 million in net proceeds from stock and warrants during the nine months ended September 30, 2025. However, these funds were insufficient to cover the operating losses, highlighting a reliance on continuous capital raises.
• Dilution from Stock Issuances [medium — financial]: Shares outstanding increased significantly from 10,536,875 at December 31, 2024, to 29,705,360 at September 30, 2025. This substantial dilution impacts existing shareholders and may affect future stock performance.
• Decreased Government Contract Revenue [medium — operational]: Revenue from government contracts dropped to $0 for Q3 2025 from $2,789,484 in Q3 2024. This significant decline suggests a potential loss of key contracts or a shift in business focus, impacting revenue streams.
• Rising General and Administrative Expenses [low — operational]: General and administrative expenses increased to $1,329,711 for Q3 2025 from $1,241,176 in Q3 2024. While R&D expenses decreased, the rise in G&A adds to the overall cost structure.

Industry Context

GeoVax Labs operates in the biotechnology sector, specifically focusing on vaccine development. This industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. The competitive landscape includes large pharmaceutical companies and numerous smaller biotech firms, all vying for funding and market share in areas like infectious diseases and oncology.

Regulatory Implications

As a biotech company, GeoVax is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet regulatory standards, or changes in regulatory requirements can significantly impact development timelines and market access. Compliance with evolving safety and efficacy standards is paramount.

What Investors Should Do

1. Monitor cash burn rate and future financing activities.
2. Evaluate the impact of declining government contract revenue.
3. Assess the progress and potential of the R&D pipeline.
4. Consider the impact of share dilution.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $6,318,914 and cash balance of $5,008,997, with explicit going concern warning.
• 2025-09-30: End of Nine Months 2025 — Year-to-date net loss of $17,046,348, with significant increase in shares outstanding.
• 2025-09-30: Completion of $2.3 million offering — Part of the capital raising efforts to sustain operations, but insufficient to alleviate going concern issues.
• 2025-07-31: Completion of $5.5 million offering — Another capital infusion to fund operations and development activities.
• 2025-03-31: Completion of $4.1 million offering — Initial significant capital raise in 2025, contributing to the total proceeds from stock and warrants.
• 2024-12-31: End of Fiscal Year 2024 — Reported cash balance of $5,506,941 and 10,536,875 shares outstanding, providing a baseline for 2025 performance.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company has historically operated at a loss, contributing to its current financial challenges.)

Going concern

An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. (The company's explicit statement about its cash sufficiency raises doubt about its ability to continue as a going concern, a critical indicator for investors and creditors.)

Additional paid-in capital

The amount of capital that shareholders have paid to the company for stock in excess of its par value. (Shows the significant capital raised through stock issuances, which has been substantial but not enough to cover losses.)

Weighted average shares outstanding

The average number of a company's outstanding shares over a period, used to calculate earnings per share. (The significant increase in weighted average shares outstanding in 2025, from 3,701,145 in YTD 2024 to 17,494,429 in YTD 2025, explains the reduction in net loss per share despite higher net losses.)

ATM program

At-the-Market program, a method for publicly traded companies to sell shares of their stock over time. (Represents a continuous source of funding for the company, contributing $4.0 million to its capital in the nine months ended September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year, GeoVax Labs has seen a significant decline in revenue from government contracts, which fell to $0 in Q3 2025 from $2,789,484 in Q3 2024. While operating expenses, particularly R&D, have decreased, net losses have widened due to the revenue drop. The company has also experienced substantial dilution, with shares outstanding more than doubling, leading to a lower net loss per share despite the increased overall loss. A critical new risk factor is the explicit statement regarding the company's ability to continue as a going concern, a concern not highlighted in the same manner previously.

Key Financial Figures

• $0.001 — ange on which Registered Common Stock $0.001 par value GOVX The Nasdaq Capital M

Filing Documents

• govx20250930_10q.htm (10-Q) — 679KB
• ex_884832.htm (EX-10.5) — 203KB
• ex_884833.htm (EX-10.6) — 350KB
• ex_884834.htm (EX-31.1) — 12KB
• ex_884835.htm (EX-31.2) — 13KB
• ex_884836.htm (EX-32.1) — 4KB
• ex_884837.htm (EX-32.2) — 4KB
• portal_logo.jpg (GRAPHIC) — 9KB
• 0001437749-25-034811.txt ( ) — 3859KB
• govx-20250930.xsd (EX-101.SCH) — 34KB
• govx-20250930_def.xml (EX-101.DEF) — 198KB
• govx-20250930_lab.xml (EX-101.LAB) — 193KB
• govx-20250930_pre.xml (EX-101.PRE) — 222KB
• govx-20250930_cal.xml (EX-101.CAL) — 25KB
• govx20250930_10q_htm.xml (XML) — 379KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1 Condensed Consolidated Financial Statements: 1 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations for the three-month and nine-month periods ended September 30, 2025 and 2024 (unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Equity for the three-month and nine-month periods ended September 30, 2025 and 2024 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the nine-month periods ended September 30, 2025 and 2024 (unaudited) 4 Notes to Condensed Consolidated Financial Statements (unaudited) 5 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 9 Item 3

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 15 Item 4

Controls and Procedures

Controls and Procedures 15

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1

Legal Proceedings

Legal Proceedings 16 Item 1A

Risk Factors

Risk Factors 16 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 16 Item 3 Defaults Upon Senior Securities 16 Item 4 Mine Safety Disclosures 16 Item 5 Other Information 16 Item 6 Exhibits 17

-- FINANCIAL INFORMATION

Part I -- FINANCIAL INFORMATION Item 1

Financial Statements

Financial Statements GEOVAX LABS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2025 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 5,008,997 $ 5,506,941 Government contract receivable - 659,409 Prepaid expenses and other current assets 1,508,251 1,768,533 Total current assets 6,517,248 7,934,883 Property and equipment, net 127,060 149,974 Other assets 86,947 71,010 Total assets $ 6,731,255 $ 8,155,867 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 976,411 $ 1,849,760 Accrued expenses 847,766 1,257,572 Total current liabilities 1,824,177 3,107,332 Commitments (Note 4) Stockholders' equity: Common stock, $ .001 par value: Authorized shares – 150,000,000 Issued and outstanding shares – 29,705,360 and 10,536,875 at September 30, 2025 and December 31, 2024, respectively 29,705 10,537 Additional paid-in capital 151,279,802 134,394,079 Accumulated deficit ( 146,402,429 ) ( 129,356,081 ) Total stockholders' equity 4,907,078 5,048,535 Total liabilities and stockholders' equity $ 6,731,255 $ 8,155,867 See accompanying notes to condensed consolidated financial statements. 1 GEOVAX LABS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenue from government contract $ - $ 2,789,484 $ 2,489,145 $ 3,090,161 Operating expenses: Research and development 5,043,504 7,402,884 15,127,090 16,105,480 General and administrative 1,329,711 1,241,176 4,559,346 3,784,559 Total operating expenses 6,373,215 8,644,060 19,686,436 19,890,039 Loss from operations ( 6,373,215 ) ( 5,854,576 ) ( 17,197,291 ) ( 16,799,878 ) Other income (expense): Interest income 54,301 53,191 150,943 91,611 Interest expense - ( 14,083 ) - ( 21,375 ) T

Forward-Looking Statements

Forward-Looking Statements Information included in this Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the " Exchange Act " ). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words " believes, " " expects, " , " looks forward to " , " may " , " estimates " , " continues " , " should " , " could " , " target " , " potential, " " intends, " " plans, " " anticipates, " " likely, " " will " and similar expressions to identify forward-looking statements. All statements in this Quarterly Report, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, future governmental grants, projected costs, prospects, plans, intentions, expectations and objectives could be forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. We operate in a highly competitive, highly regulated and rapidly changing environment and our business is constantly evolving. Therefore, it is likely that new risks will emerge, and that the nature and elements of existing risks will change, over time. It is not possible for management to predict all such risk factors or changes therein, or to assess either the impact of al

View Full Filing

View this 10-Q filing on SEC EDGAR